A marker for Stevens-Johnson syndrome ...: ethnicity matters. - Wikidata - wikimedia - TriplyDB

A marker for Stevens-Johnson syndrome ...: ethnicity matters.

A marker for Stevens-Johnson syndrome ...: ethnicity matters.

http://www.wikidata.org/entity/Q34485108

about

Toxic epidermal necrolysis and Stevens-Johnson syndrome Drug induced exfoliative dermatitis: state of the art New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity Idiosyncratic adverse drug reactions: current concepts Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation The Absence of CYP3A5*3 Is a Protective Factor to Anticonvulsants Hypersensitivity Reactions: A Case-Control Study in Brazilian Subjects Comparison of a New In-House and Three Published HLA-B*15:02 Screening Methods for Prevention of Carbamazepine-Induced Severe Drug Reactions Distributions of HLA-A and -B alleles and haplotypes in the Yi ethnic minority of Yunnan, China: relationship to other populations Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe What are our AIMs? Interdisciplinary Perspectives on the Use of Ancestry Estimation in Disease Research.Expectations, validity, and reality in pharmacogenetics.The risk of cutaneous adverse reactions among patients with the HLA-A* 31:01 allele who are given carbamazepine, oxcarbazepine or eslicarbazepine: a perspective review Absence of HLA-B*1502 and HLA-A*3101 alleles in 9 Korean patients with antiepileptic drug-induced skin rash: a preliminary study.Pharmacogenetics of drug hypersensitivity.HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions.Problems with the collection and interpretation of Asian-American health data: omission, aggregation, and extrapolation Clinical application of pharmacogenomics.Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations.Drug hypersensitivity: pharmacogenetics and clinical syndromes.Epidemiology and risk factors for drug allergy.PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.HapMap, pharmacogenomics, and the goal of personalized prescribing Bibliometric analysis of literature on toxic epidermal necrolysis and Stevens-Johnson syndrome: 1940 - 2015 Antecedent Drug Exposure Aetiology and Management Protocols in Steven-Johnson Syndrome and Toxic Epidermal Necrolysis, A Hospital Based Prospective Study Systems biology approaches for identifying adverse drug reactions and elucidating their underlying biological mechanisms.Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome.HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children.A case of mexiletine-induced hypersensitivity syndrome presenting as eosinophilic pneumonia.Stevens-Johnson syndrome / toxic epidermal necrolysis: an Asia-Pacific perspective.The emerging era of pharmacogenomics: current successes, future potential, and challenges.Genomic architecture of pharmacological efficacy and adverse events.Early toxic epidermal necrolysis syndrome post-intra-cranial tumor resection.Recent advances in the understanding of severe cutaneous adverse reactions.Prevention of severe cutaneous adverse drug reactions: the emerging value of pharmacogenetic screening The p-i Concept: Pharmacological Interaction of Drugs With Immune Receptors.Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Associations, Outcomes, and Pathobiology-Thirty Years of Progress but Still Much to Be Done.PharmGKB summary: carbamazepine pathway.

P2860

Q21202877-CBCC4252-D955-4912-8DA4-3A3D1BC6F676 Q26739886-3A81C05F-5F0F-4F3C-BDDC-DC448250AAC5 Q26800976-511D6DA3-7061-44D9-92CF-6A8072D5159E Q26824391-5ED8FFBF-F7C0-43E2-A4D7-E397586D157D Q28076600-852F5131-C96C-4E9E-9E0F-7342BF525170 Q28547386-AD7FA7A8-C224-43BC-AEFB-ED786817494C Q28552275-756A74DA-D0DF-4177-9587-23AE42EC1F4C Q28749095-7B445991-2ACC-43B6-B7BD-D9A1D8B7D09F Q28943413-67521147-DD9F-4B40-A1D1-44B1AF0094FA Q30600102-6D0E506F-6D1D-47C5-8A71-C5A59D7BC49E Q33926313-60A8945D-5C2C-448C-AC34-59D92B1E8814 Q34016198-CB484C20-4EF9-4416-83E8-5377C5E3EC85 Q34116637-326B3F6C-4815-4065-A847-09B1BC6ED8A0 Q34118186-4D0E4202-18E8-495F-8033-DF244B07528B Q34172669-6FD0AF3A-8E71-4436-BC7F-04E3CA083AD6 Q34257932-273DD514-D742-42EC-B22C-EDA4E6D806C6 Q34280673-07B56300-EE9F-4536-9DA0-B17343C16781 Q34280685-610B789D-B07E-48DF-A59E-872370611E18 Q34345953-01AFFA04-C87C-42B9-9E3C-AD3C715DF163 Q34598487-C1A11959-8DF6-4A97-B1C9-F7E251F967B1 Q34701492-2461E019-48C3-4CDA-B1C3-24057B0CD38D Q34976470-41F6073A-5462-4E68-8698-063443E8E590 Q35168561-BC01B6D5-DF58-4E45-94B8-0FF047F1E2F1 Q35827699-A7EDD4AD-D682-4EA9-ABD7-BE7A26E87C2A Q36253270-C6721158-3771-44E8-A271-A1376F8C2791 Q36541832-7BDF13F6-B2E4-4563-90D0-4FF9D5B3C8F5 Q36599215-82C6B29C-EEBA-4CC4-9BBE-B6B7A9784E26 Q36603317-751AAFC9-F842-4CE1-BEE8-EEB952895062 Q37033603-2B84A3FE-21CC-41F2-A932-548EE61EB608 Q37341208-CD3281BE-C813-484A-AEFF-AE9E1E79B4C4 Q37669205-12F9F594-B0A8-4751-B2A7-7C9F09C67F60 Q38164730-03C97BB1-3DA9-4F75-B58B-B7645BDC6E8C Q38200683-2746E8FF-ABF6-4D77-8C40-905ED6D83B43 Q38292930-DFF5A8EB-BA05-4387-B73C-158254987BE2 Q38667195-8AC3B833-FE3A-4FC4-A1AD-1D177F02542A Q38931289-2805D1CF-6199-48D3-A9C0-251B39CC2C63 Q39729427-BFF18CD8-7572-4B1F-BC63-1B2FE90C206D Q40619738-FC0FF69E-05BD-43EF-966E-DFCD4208875D Q41494133-CD31853E-1403-4DE5-A1E3-04A15D2AF27B Q42157342-3A7E7109-B2A0-4F59-84AA-50B6581D474E

P2860

A marker for Stevens-Johnson syndrome ...: ethnicity matters.

http://www.wikidata.org/entity/Q34485108

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

A marker for Stevens-Johnson syndrome ...: ethnicity matters.

@ast

A marker for Stevens-Johnson syndrome ...: ethnicity matters.

@en

A marker for Stevens-Johnson syndrome ...: ethnicity matters.

@nl

type

label

A marker for Stevens-Johnson syndrome ...: ethnicity matters.

@ast

A marker for Stevens-Johnson syndrome ...: ethnicity matters.

@en

A marker for Stevens-Johnson syndrome ...: ethnicity matters.

@nl

prefLabel

A marker for Stevens-Johnson syndrome ...: ethnicity matters.

@ast

A marker for Stevens-Johnson syndrome ...: ethnicity matters.

@en

A marker for Stevens-Johnson syndrome ...: ethnicity matters.

@nl

P1433

Q34485108-EED2A0FB-A42A-468F-9C3D-4EBC7864B36E

P1476

Q34485108-258FCF01-3AE3-40B6-BBAC-C48117FA26B4

P2093

Q34485108-0A3500F8-2BB0-4349-9C59-40D1A26B0556

Q34485108-1A35FEA4-A50E-44BD-9054-8CD119AB91BA

Q34485108-1D454238-5005-4C55-940B-83A1DAD469CD

Q34485108-3FCFDC2F-A948-4ED5-8357-548DC175789B

Q34485108-49A98E67-51BC-463F-B6F8-E1984420EB73

Q34485108-663F22D1-08AB-4290-9277-E366988F3E3E

Q34485108-9AEE7E7B-F0D4-49AB-B99A-0119D01661B3

Q34485108-9F8E845B-7791-4F1E-8D7E-47CE232C26D5

Q34485108-B7FBB62C-E9D6-4A42-AF4B-608B1E97E731

Q34485108-F59E364C-DB1F-4996-AB21-8AF8FD6A7C08

P2860

Q34485108-23DC0550-C6B5-4FE6-8B71-527B55CACB7B

Q34485108-35CB68A9-7A50-4C32-BEA5-388A8ECD80EF

Q34485108-489F2E15-0252-4011-9FCB-0EAA56CCC70C

Q34485108-57751D2B-905F-49CF-B6B4-3DEE3F164F11

Q34485108-68CAD0F8-6266-4491-A368-D26CC8FE8784

Q34485108-696AF8AA-6CE7-47D0-94A0-54B92DCD7C02

Q34485108-77307E5E-57D5-4161-A6AD-F3E8119A00A0

Q34485108-88028545-5AD3-4BAA-A9AE-99F30E29F6FD

Q34485108-990D9309-1393-4B92-911B-B81A3188E255

Q34485108-BA7C4C02-0AA2-4EAC-BAB4-E10E47650F9D

P2888

Q34485108-855BEA2A-E574-42E5-AC36-1656E2F18A91

P304

Q34485108-82E247B9-8F14-4CBD-9BF3-6CDA7B97BE6C

P31

Q34485108-93D80458-22E8-443A-94A5-99D7BA0ED822

P356

Q34485108-AD128D19-F37E-42A8-8FB0-058347BF5088

P433

Q34485108-77399F00-3A13-43D1-9C0B-AFE47E756113

P478

Q34485108-00805257-F1DE-443F-929C-C188EA88F364

P50

Q34485108-9346A856-4A4F-41A6-822A-FBCE8CA252EF

Q34485108-A8E272FB-6E12-4006-BCCF-86B077BE4437

P577

Q34485108-6B7200B6-4CB8-45B4-B86B-586886ACEB79

P5875

Q34485108-67E29ACF-4833-4630-9CE9-477201984C46

P6179

Q34485108-050E4625-EEB4-45AC-9F7A-04525C004495

P698

Q34485108-15DF0631-67C2-488E-82F7-26545D871EFD

P356

P1433

The Pharmacogenomics Journal

P1476

A marker for Stevens-Johnson syndrome ...: ethnicity matters.

@en

P2093

C de Toma

http://www.w3.org/2001/XMLSchema#string

E Graf

http://www.w3.org/2001/XMLSchema#string

H LeLouet

http://www.w3.org/2001/XMLSchema#string

J-C Roujeau

http://www.w3.org/2001/XMLSchema#string

L Thomas

http://www.w3.org/2001/XMLSchema#string

M Mockenhaupt

http://www.w3.org/2001/XMLSchema#string

M Schumacher

http://www.w3.org/2001/XMLSchema#string

N Borot

http://www.w3.org/2001/XMLSchema#string

N Ledger

http://www.w3.org/2001/XMLSchema#string

RegiSCAR Group

http://www.w3.org/2001/XMLSchema#string

P2860

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

Medical genetics: a marker for Stevens-Johnson syndrome

Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism.

Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist?

Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.

Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

The three-dimensional structure of peptide-MHC complexes.

P2888

P304

265-268

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.TPJ.6500356

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Alain Hovnanian

P577

2006-01-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7356321

http://www.w3.org/2001/XMLSchema#string

P6179

1050700804

http://www.w3.org/2001/XMLSchema#string

P698

16415921

http://www.w3.org/2001/XMLSchema#string